FDA approves inhalable diabetes drug Afrezza

The U.S. Department of Health and Human Services building which houses the Food and Drug Administration (FDA) in Rockville, MD. (File) (Getty Images)
The U.S. Department of Health and Human Services building which houses the Food and Drug Administration (FDA) in Rockville, MD. (File) (Getty Images)
Set Text Size SmallSet Text Size MediumSet Text Size LargeSet Text Size X-Large
Share
Updated: 6/27 6:42 pm

WASHINGTON (AP) — The Food and Drug Administration on Friday said that it has approved a long-delayed inhalable diabetes medication, designed to help patients control their blood sugar levels.

The FDA cleared MannKind Corp.'s drug Afrezza, a fast-acting form of insulin, for adults with the most common form of diabetes, which affects more than 25 million Americans. The approval decision comes more than three years after the agency first asked MannKind to run additional clinical studies on the drug.

Afrezza, an insulin powder, comes in a single-use cartridge and is designed to be inhaled at the start of a meal. MannKind has said patients using the drug can achieve peak insulin levels within 12 to 15 minutes. 

That compares to a wait time of an hour and a half or more after patients inject insulin.

©2014 Associated Press. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Share
Inergize Digital This site is hosted and managed by Inergize Digital.

WTVQ.com supports children's privacy rights. All persons under the age of 13 MUST have parental permission to use this website and direct parental supervision is strongly recommended.